PCM
CMPX icon

Prelude Capital Management’s Compass Therapeutics CMPX Stock Holding History

Prelude Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$95.2K Buy
18,000
+8,000
+80% +$46.2K 0.01% 1062
2025
Q4 		$53.7K Buy
+10,000
New +$46.2K ﹤0.01% 1235

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Prelude Capital Management's CMPX Position: Q1 2026 in Review

Prelude Capital Management increased its Compass Therapeutics (CMPX) stake by 80% in Q1 2026, buying an estimated $46.2K and bringing the position to 18,000 shares worth $95.2K. The position accounts for 0.01% of the portfolio, ranked #1062.

Prelude Capital Management first reported a position in CMPX in Q4 2025 and has held it in 2 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Prelude Capital Management held 18,000 shares of Compass Therapeutics worth $95.2K as of Q1 2026.
  • Prelude Capital Management bought 8,000 Compass Therapeutics shares in Q1 2026, an estimated $46.2K.
  • Compass Therapeutics made up 0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1062 holding.
  • Prelude Capital Management first reported a position in Compass Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.